Table 2. Logistic regression analysis of response status by statin and escitalopram use in the EsDEPACS trial.

	HAM-D response (1 year)		BDI response (1 year)		HAM-D response (24 weeks)		BDI response (24 weeks)
	OR (95% CI)	P-value	OR (95% CI)	P-value	OR (95% CI)	P-value	OR (95% CI)	P-value
	ITT set
Statin use	2.23 (1.11–4.51)	0.025	2.82 (1.35–5.90)	0.006	1.81 (0.94–3.50)	0.078	1.74 (0.89–3.41)	0.108
Escitalopram use	1.57 (0.90–2.75)	0.111	1.40 (0.79–2.49)	0.250	2.18 (1.23–3.85)	0.007	2.55 (1.43–4.55)	0.002
	Efficacy set
Statin use	2.84 (1.32–5.87)	0.005	3.32 (1.57–7.05)	0.002	NA		NA
Escitalopram use	2.35 (1.29–4.31)	0.006	1.88 (1.02–3.47)	0.044

Abbreviations: BDI, Beck Depression Inventory; CI, confidence interval; EsDEPACS, the Escitalopram for Depression in Acute Coronary Syndrome trial; HAM-D, Hamilton Depression Rating Scale; ITT, intention-to-treat; NA, not applicable; OR, odds ratio.

Adjusted for baseline score of depressive measure, obesity, hypertension, total cholesterol level, myocardial infarction diagnosis, Killip class and each use of statin and escitalopram.

The efficacy set group excluded subjects who were randomly assigned to the escitalopram arm but discontinued the trial immediately after the baseline visit.

Values in bold show statistical significance (P-value=0.05).